Erenumab is a Monoclonal Antibody owned by Amgen, and is involved in 51 clinical trials, of which 32 were completed, 18 are ongoing, and 1 is planned.
Erenumab is a human monoclonal antibody that antagonizes the calcitonin gene-related peptide (CGRP) receptor. The product binds to the extracellular domain of the CGRP-R and prevents interaction with the neuropeptide CGRP.
The revenue for Erenumab is expected to reach a total of $9.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Erenumab NPV Report.
Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human immunoglobulin G2 (IgG2) monoclonal antibody. It is formulated as solution in a single-dose for sub-cutaneous route of administration. Erenumab is indicated for the preventive treatment of migraine in adults.
Erenumab (AMG-334) is under development for the treatment of chronic cluster headache, an episodic migraine and chronic migraine. The drug candidate is administered intravenously or subcutaneously as form an of a solution.
It is under development for rosacea, temporomandibular disorder (TMD) pain, migraine in adults and pediatric patients, persistent headache attributed to mild traumatic brain injury (persistent post-traumatic headache) and trigeminal neuralgia. It was also under development for the treatment of hot flashes associated with menopause and stable angina.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.
The company reported revenues of (US Dollars) US$25,979 million for the fiscal year ended December 2021 (FY2021), an increase of 2.2% over FY2020. In FY2021, the company’s operating margin was 29.4%, compared to an operating margin of 35.9% in FY2020. In FY2021, the company recorded a net margin of 22.7%, compared to a net margin of 28.6% in FY2020. The company reported revenues of US$6,652 million for the third quarter ended September 2022, an increase of 0.9% over the previous quarter.
Quick View – Erenumab
|Highest Development Stage|